Registry for Advanced Sarcodiosis

NCT ID: NCT03769987

Last Updated: 2018-12-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

800 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-01-01

Study Completion Date

2020-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Registry with evaluation and genetic information of patients with advanced sarcoidosis and matched sarcoidosis

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcoidosis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

neurosarcoidosis, pulmonary hyeprtension, infliximab, repository corticotropin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

observation

observe patients every 6 months

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with diagnosis of sarcoidosis based on ATS/WASOG criteria 22
* Age ≥ 18 years.
* Life expectancy of at least 2 years.
* Pulmonary function tests (spirometry) within one month of entry or willing to under pulmonary function testing on the day of study enrollment
* Sarcoidosis as characterized as either advanced or non-advanced (see protocol for definition of advanced disease)
* Subjects must be able to understand and be willing to sign the written informed consent form. A signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure.

Exclusion Criteria

* Subjects with a medical disorder, condition, or history of such that would impair the subject's ability to participate or complete this study in the opinion of the investigator
* Inability to comply with the protocol and/or not willing or not available for follow-up assessments.
* Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation.
Minimum Eligible Age

15 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Cincinnati

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Robert P Baughman

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Robert Baughman

Role: STUDY_CHAIR

University of Cincinnati

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Cincinnati

Cincinnati, Ohio, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Robert Baughman

Role: CONTACT

Phone: 513-584-5225

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Robert P Baughman, MD

Role: primary

Elyse E Lower

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

REAS

Identifier Type: -

Identifier Source: org_study_id